4
Participants
Start Date
May 23, 2011
Primary Completion Date
September 13, 2012
Study Completion Date
September 13, 2012
Erlotinib
continuous oral Erlotinib 85 mg/m\^2 per day
Childrens Hospital of Pittsburgh of UPMC, Pittsburgh
Children's National Medical Center -D.C. Center for Cancer and Blood Disorders, Washington D.C.
Emory University Children's Healthcare of Atlanta, Atlanta
University of Miami, Miami
University of Alabama at Birmingham, Birmingham
University of Minnesota - Amplatz Children's Hospital, Minneapolis
The Children's Hospital Center for Cancer and Blood Disorders, Aurora
Children's Hospital of Orange County (CHOC), Orange
Packard Children's Hospital, Palo Alto
Oregon Health & Sciences University Doernbecher Children's Hospital, Portland
University of Wisconsin, Madison
Stollery Children's Hospital, Edmonton
Children's and Women's Health Center of BC, Vancouver
Hospital for Sick Children, Toronto
Birmingham Children's Hospital Oncology Department, Birmingham
Royal Hospital for Sick Children, Glasgow
Paediatric Oncology and Haematology Offices,, Leeds
Alder Hey Children's NHS Foundation Trust, Liverpool
Royal Manchester Children's Hospital Ward 84, Manchester
University of Nottingham, Nottingham
Royal Marsden Hospital, Sutton
Lead Sponsor
OSI Pharmaceuticals
INDUSTRY